American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Original Article
Neuropsychopharmacology (2002) 26 325-339.10.1038/S0893-133X(01)00312-8

Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum

Junji Ichikawa MD, Ph.D, Jin Dai MD, Ian A O'Laughlin BS, Wiley L Fowler MS and Herbert Y Meltzer MD
Departments of Psychiatry and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

Correspondence: Dr Junji Ichikara, 1601 23rd Avenue South, The First Floor Laboratory R-1117, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212, USA

ABSTRACT

The role of acetylcholine (ACh) in the action of antipsychotic drugs (APDs) was studied by microdialysis, without AChesterase inhibition, to facilitate the interpretation of any observed drug effects. The atypical APDs, clozapine (2.5-20 mg/kg), olanzapine (10 mg/kg), risperidone (1 mg/kg), and ziprasidone (3 mg/kg) significantly increased ACh release in rat medial prefrontal cortex (mPFC), whereas the typical APDs, haloperidol (0.1-1 mg/kg), S(-)-sulpiride (10-25 mg/g), and thioridazine (5-20 mg/kg) did not. None of seven APDs increased ACh release in the nucleus accumbens or striatum at the doses effective in the mPFC. Thus, atypical and typical APDs may differ in the ability to increase cortical ACh release, a possible factor contributing to cognitive improvement in schizophrenia. After perfusion with neostigmine, an AChesterase inhibitor, clozapine, but not haloperidol, increased ACh release in all three aforementioned brain regions with an enhanced effect in the mPFC, indicating the importance of studying ACh release in the absence of AChesterase inhibition. Clozapine, and perhaps other atypical APDs, alone or in combination with an AChesterase inhibitor, may improve cognition in schizophrenia, and perhaps other cognitive disorders, e.g., early Alzheimer's disease, by enhancing cortical cholinergic transmission.

Keywords: Typical and atypical antipsychotic drugs; Acetylcholine release; Medial prefrontal cortex; Nucleus accumbens; Striatum; Schizophrenia
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
Full Text Full Text
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 2002 by the American College of Neuropsychopharmacology